Clinical trials: Pomalidomide
Multiple Myeloma
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM
The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat, pomalidomide, and dexamethasone and to establish the recommended Phase 2 dose for combination treatment to…
- Trial name
- NCT07150104
- Testing
- Belantamab mafodotin, Nirogacestat, Pomalidomide
- Where
- 10 sites in Brazil, Canada and 6 more
- Volunteers
- 14 people
- Sponsor
- GlaxoSmithKline
Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia
A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
The purpose of this study is to determine the safety of and to select a treatment regimen of pomalidomide (CC-4047) either as single-agent or in combination with prednisone to study further in patients with myelofibrosis with…
- Conditions
- Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia, Myelofibrosis
- Trial name
- NCT00463385
- Testing
- Pomalidomide, Prednisone
- Where
- 11 sites in United States, Austria and 3 more
- Volunteers
- 88 people
- Sponsor
- Celgene
Graft vs Host Disease, Graft-Versus-Host Disease
Pomalidomide for Chronic Graft-versus-Host Disease
Background: Pomalidomide is a drug that alters the body's immune response. It may help people who have chronic graft-versus-host disease (GvHD).
- Trial name
- NCT01688466
- Testing
- Pomalidomide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.
Study of elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd Cohort) and elotuzumab in combination with nivolumab (EN Cohort) to assess the safety and efficacy of these combination therapies for treatment…
- Trial name
- NCT02612779
- Testing
- Elotuzumab, Pomalidomide, Dexamethasone
- Where
- 22 sites in United States
- Volunteers
- 74 people
- Sponsor
- Bristol-Myers Squibb
Relapsed and/or Refractory Multiple Myeloma
A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma
The main aim of this study is to learn if ixazomib, given with dexamethasone, stops the cancer from getting worse in people with relapsed or refractory multiple myeloma.
- Trial name
- NCT03170882
- Testing
- Ixazomib, Pomalidomide, Dexamethasone
- Where
- 111 sites in United States, Australia and 16 more
- Volunteers
- 122 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma
Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase I/II trial studies the side effects and the best dose of pomalidomide when given together with dexamethasone and filgrastim-sndz and to see how well they work in treating patients with multiple myeloma that has…
- Conditions
- Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT01946152
- Testing
- Dexamethasone, Filgrastim-sndz, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Kaposi Sarcoma, Sarcoma, Kaposi
Pomalidomide for Kaposi Sarcoma in People With or Without HIV
Background: Pomalidomide is a drug that can treat cancer through several mechanisms. It is taken by mouth (orally). Pomalidomide can help treat cancer by blocking certain factors that promote tumor growth or by stimulating the…
- Trial name
- NCT01495598
- Testing
- Pomalidomide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Telangiectasia, Hereditary Hemorrhagic
Pomalidomide for the Treatment of Bleeding in HHT
This is a Phase II placebo-controlled double-blind study of pomalidomide in patients with hereditary hemorrhagic telangiectasia (HHT) with moderate to severe epistaxis who have anemia and/or require parenteral iron infusions or…
- Trial name
- PATH-HHT (NCT03910244)
- Testing
- Pomalidomide Oral Product
- Where
- 14 sites in United States
- Volunteers
- 145 people
- Sponsor
- The Cleveland Clinic
Plasma Cell Myeloma
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients
Primary Objective: To demonstrate the benefit of isatuximab in combination with pomalidomide and low-dose dexamethasone in the prolongation of Progression Free Survival (PFS) as compared to pomalidomide and low-dose dexamethasone…
- Trial name
- ICARIA-MM (NCT02990338)
- Testing
- Isatuximab, Pomalidomide, Dexamethasone
- Where
- 111 sites in United States, Australia and 22 more
- Volunteers
- 307 people
- Sponsor
- Sanofi
Multiple Myeloma
An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)
The purpose of this study is to determine if adding Elotuzumab to Pomalidomide and low-dose dexamethasone is a more effective treatment of relapsed and refractory multiple myeloma compared to pomalidomide and low-dose…
- Trial name
- NCT02654132
- Testing
- Elotuzumab, Pomalidomide, Dexamethasone
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 117 people
- Sponsor
- Bristol-Myers Squibb
Refractory Plasma Cell Myeloma
Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma
This phase II trial studies how well dexamethasone, elotuzumab, pomalidomide work in treating patients with multiple myeloma that has not responded to previous treatment.
- Trial name
- NCT03713294
- Testing
- Dexamethasone, Elotuzumab, Pomalidomide
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone compared with that of combination of pomalidomide, bortezomib and dexamethasone in Japanese participants…
- Trial name
- DREAMM 8 (NCT06956170)
- Testing
- Belantamab mafodotin, Pomalidomide, Dexamethasone
- Where
- 13 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
Waldenstrom's Macroglobulinemia
Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia
Pomalidomide is a newly discovered drug that may stop cancer cells from growing abnormally. Pomalidomide may also stimulate the immune system to fight the cancer cells and possibly improve the effectiveness of dexamethasone and…
- Trial name
- NCT01078974
- Testing
- pomalidomide, dexamethasone, rituximab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Steven P. Treon, MD, PhD
Multiple Myeloma
PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma
To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
- Trial name
- NCT03269136
- Testing
- PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, PF-06863135 + lenalidomide
- Where
- 37 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- Pfizer
Multiple Myeloma
Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Phase 1 is an open-label, dose finding, multicenter study of ibrutinib in combination with pomalidomide and dexamethasone in subjects with relapsed/refractory multiple myeloma.
- Trial name
- NCT02548962
- Testing
- Ibrutinib, Pomalidomide, Dexamethasone
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 11 people
- Sponsor
- Pharmacyclics LLC.
Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
CC-4047 in Treating Patients With Myelofibrosis
RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in different ways and stop cancer cells from growing. CC-4047 may also stop the growth of cancer cells by blocking blood flow to the cancer.
- Trial name
- NCT00669578
- Testing
- CC-4047
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Mayo Clinic
Plasma Cell Myeloma Recurrent
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
This will be randomized, multicenter, Phase 3, open-label study evaluating subcutaneous (SC) vs intravenous (IV) administration of isatuximab in combination with pomalidomide and dexamethasone (Pd) in RRMM patients (study…
- Trial name
- IRAKLIA (NCT05405166)
- Testing
- Isatuximab IV, Isatuximab SC, Dexamethasone
- Where
- 128 sites in United States, Argentina and 19 more
- Volunteers
- 531 people
- Sponsor
- Sanofi
Multiple Myeloma
Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma
Lenalidomide has clinical activity in myeloma. The closely related compound, Pomalidomide, may have clinical activity in patients who have previously been treated with lenalidomide and who no longer respond to it.
- Trial name
- NCT01319422
- Testing
- Pomalidomide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Yale University
Multiple Myeloma
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody…
- Trial name
- DREAMM 5 (NCT04126200)
- Testing
- Belantamab mafodotin, GSK3174998, Feladilimab
- Where
- 38 sites in United States, Brazil and 11 more
- Volunteers
- 208 people
- Sponsor
- GlaxoSmithKline
Relapsed or Refractory Multiple Myeloma
Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma
A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in participants with relapsed refractory multiple myeloma.
- Trial name
- INTREPID-1 (NCT02939183)
- Testing
- Immediate Release (IR) Formulation, Gastro-Retentive (GR) Formulation, Dexamethasone
- Where
- 20 sites in United States, Australia and 2 more
- Volunteers
- 61 people
- Sponsor
- Amgen